Coherus market cap

Author: dzmd

August undefined, 2024

WebAs of April 2024 Coherus BioSciences has a market cap of $0.59 Billion. This makes Coherus BioSciences the world's 5195th most valuable company by market cap according to our data. The market capitalization, … WebApr 11, 2024 · A high-level overview of Coherus BioSciences, Inc. (CHRS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

Coherus BioSciences, Inc. (CHRS) - Stock Analysis

WebOct 17, 2024 · CHRS has a market cap of $1.34bn and a cash reserve of $455mn. They have a short interest of 11.7% as of today. In the previous quarter, they made net revenue of $88mn, mainly on the back of... WebCoherus BioSciences, Inc. (CHRS) Stock Price, News, Quote & History - Yahoo Finance S&P 500 Dow 30 Nasdaq +91.09 Russell 2000 +2.33(+0.13%) Crude Oil -0.24(-0.30%) Gold Coherus BioSciences,... livy summary

Is Coherus Biosciences Inc (CHRS) A Good Stock To Buy - Yahoo …

Web$7.66 (As of Thursday Closing) General Information Description Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of … WebJun 18, 2024 · CHRS has a market cap of $1.08bn and a cash balance of $399mn. Last year, the company had nearly half a billion dollar in product revenue. Bottom line The standard gripe of investors with CHRS... WebApr 9, 2024 · The stock has a market cap of $609.81 million, a P/E ratio of -2.04 and a beta of 0.95. Coherus BioSciences, Inc. has a 1-year low of $5.58 and a 1-year high of $14.11. camp muskoka ontario

Coherus BioSciences (CHRS) Stock Forecast, Price & News

Coherus Biosciences Company Profile: Stock Performance

WebCurrent and historical earnings charts for Coherus BioSciences . As of April 2024 Coherus BioSciences 's TTM earnings are -$0.26 B. companies: 7,323 total market cap: $86.813 T. ... The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company. In most cases it can be easily calculated by multiplying the ... WebMar 6, 2024 · Coherus BioSciences, Inc. provided earnings guidance for the year 2024 and 2024. For the year, the company expects significant topline revenue growth. ... Capitalization: 621 M 621 M-EV / Sales 2024: 3,12x: EV / Sales 2024: 1,61x: Nbr of Employees: 359: Free-Float: 89,9%: More Financials. campus jorge vassilakisWeb18 hours ago · The Price to Free Cash Flow ratio or P/FCF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator ... lixin tao

"WebAbout Coherus Immuno-oncology Dedicated to Improving Patient Lives by Expanding Access to Life-Changing Biologic Medicines Our approved products span multiple therapeutic areas including oncology, … " - Coherus market cap

Coherus market cap

Coherus: Does The Market Need Another Anti-PD1? - SeekingAlpha

WebMar 30, 2024 · Market Cap Chart Since November 6, 2014, Coherus BioSciences, Inc.'s market cap has increased from $103.23M to $513.48M, an increase of 397.41%. That is … WebMar 6, 2024 · Coherus BioSciences, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $45.35 million for the quarter ended December 2024, missing the Zacks Consensus...

Did you know?

WebDec 7, 2024 · According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Rubric Capital Management, managed by David Rosen, holds the largest position in... WebAug 19, 2024 · Coherus’ market cap is US$1 billion, the forward P/E one year is -4.46, the EPS is US$-2.32, and the 52-week highest and the lowest stock price of the company was US$22.22 and US$12.21. The stock fell 18.64 percent YTD. Also read: Check out these fastest-growing small-cap healthcare stocks

WebAbout Coherus. Leadership Team; Board of Directors; Scientific Advisory Board; Immuno-oncology Scientific Advisory Board; Commercial Advisory Committee; Contact Us; … WebFeb 28, 2024 · The Investor Relations website contains information about Coherus BioSciences, Inc.'s business for stockholders, potential investors, and financial ...

Web2 days ago · Get a real-time Coherus BioSciences, Inc. (CHRS) stock price quote with breaking news, financials, statistics, charts and more. ... Market Cap: 620.96M: Revenue (ttm) 211.04M: Net Income (ttm)-291.75M: Shares Out ... 3, 2024: About CHRS. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno … WebFind real-time CHRS - Coherus BioSciences Inc stock quotes, company profile, news and forecasts from CNN Business. CHRS - Coherus BioSciences Inc Stock quote - …

WebApr 12, 2024 · The average twelve-month price prediction for Coherus BioSciences is $16.50 with a high price target of $26.00 and a low price target of $11.00. Do Wall Street analysts like Coherus BioSciences more than its competitors? Analysts like Coherus BioSciences more than other Medical companies.

WebGet the latest Coherus Biosciences Inc (CHRS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and … campus liselotteWebCoherus BioSciences market cap history and chart from 2013 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the … campus kajee oefensiteWebJan 31, 2024 · Coherus has a market cap valuation of $633m at the time of writing, yet the company - according to a presentation delivered at this year's JP Morgan Healthcare … li xinxin tuftsWebMarket Cap. Historical daily share price chart and data for Coherus BioSciences since 2024 adjusted for splits. The latest closing stock price for Coherus BioSciences as of March … lix tokenWebJan 9, 2024 · CHRS has a market cap of $777mn and a cash reserve of $286mn. In November, Coherus revised the guidance range of combined 2024 R&D and SG&A expenses from $375 - $395 million to a range of … lixivaptanWebView the latest Coherus BioSciences Inc. (CHRS) stock price, news, historical charts, analyst ratings and financial information from WSJ. CHRS Coherus BioSciences Inc. … lixisenatide parkinsonWebApr 12, 2024 · According to analysts' consensus price target of $16.50, Coherus BioSciences has a forecasted upside of 120.9% from its current price of $7.47. Amount of Analyst Coverage Coherus BioSciences has … camp taylor louisville ky